Supporting Healthy Moms and Babies Act

The 'Supporting Healthy Moms and Babies Act' (HR3762) was introduced in the House on June 5, 2025, and subsequently referred to the Committees on Energy and Commerce, Ways and Means, and Education and Workforce. This bill aims to amend the Patient Protection and Affordable Care Act to include comprehensive prenatal, childbirth, neonatal, perinatal, and postpartum care and screenings as essential health benefits, explicitly preventing cost-sharing requirements for these services. A companion bill, S1834, has been introduced in the Senate, indicating bipartisan and bicameral interest in the policy. This bill does not authorize or appropriate a specific dollar amount. Instead, it mandates that health insurance plans cover specific services without cost-sharing, effectively shifting the financial burden from individuals to health insurers. This regulatory change would directly increase revenue streams for healthcare providers, diagnostic companies, and medical device manufacturers involved in maternal and newborn care. Conversely, it would increase costs for health insurers, as they would be required to cover these services without the ability to pass on cost-sharing to consumers. Structural winners under this legislation, if enacted, would include healthcare providers and diagnostic companies. Companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX), which provide diagnostic services, would see increased demand for screenings. Medical device companies such as Teleflex Incorporated ($TFX) and GE HealthCare Technologies Inc. ($GEHC), which supply equipment and devices for maternal and newborn care, would also benefit from increased utilization of services. Health insurers, including UnitedHealth Group Incorporated ($UNH), The Cigna Group ($CI), and Humana Inc. ($HUM), would face increased costs due to the expanded coverage requirements. CVS Health Corporation ($CVS), with its integrated health services and insurance offerings, would experience mixed impacts, with increased service demand potentially offset by higher insurance costs. Looking at recent market data, health insurers like UnitedHealth Group ($UNH), Cigna Group ($CI), and Humana Inc. ($HUM) have shown positive 7-day changes of +7.48%, +6.82%, and +10.03% respectively, despite the potential for increased costs from this type of legislation. However, their 30-day changes are mixed, with UNH at -2.57%, CI at -1.98%, and HUM at +1.05%. Diagnostic companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) have also seen positive 7-day changes of +4.12% and +0.91%. Medical device companies Teleflex Incorporated ($TFX) and GE HealthCare Technologies Inc. ($GEHC) show 7-day changes of +0.1% and +2.37%. The bill is in the early stages of the legislative process, having been referred to multiple committees in the House. The existence of a companion bill in the Senate (S1834) suggests coordinated legislative effort, but significant steps, including committee hearings, markups, and floor votes in both chambers, remain before potential enactment.